Clinical trial

Real-life Pan-HER-blockade With Neratinib

NCT04388384

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2020-07-02

PhaseN/A

Study timeline

Study start (actual)2020-07-02Date precision: day

Registry last updated2025-08-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Neoplasmunresolved

Interventions

NeratinibDRUG · verified · RxNorm: neratinib

Sponsors & collaborators

Pierre Fabre Pharma GmbHlead sponsor

iOMEDICO AGcollaborator

Pierre Fabre Pharma Austriacollaborator

Pierre Fabre Pharma AGcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04388384 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.